Introduction {#S0001}
============

Freezing of gait (FOG) mainly occurs in the advanced stage of Parkinson's disease (PD) which leads to higher fall risk and poorer prognosis. It is mainly manifested by a sudden transient gait disorder during walking, most commonly when starting to walk and turning.[@CIT0001] FOG is a phenomenon that occurs most often during the "off" state, but it may also happen during the "on" state. The relationship between FOG and dopaminergic medication is complex. Most FOG could be relieved by levodopa dose adjustments, particularly those with FOG during the "off" state.[@CIT0002],[@CIT0003] But "on" FOG may be induced by dopaminergic drugs.[@CIT0004] The mechanism of freezing gait is not completely clear. Lesions of the cortex, brainstem, and basal ganglia were reported to be involved in the pathogenesis of FOG. The study of basal ganglia by molecular imaging has attracted more attention.[@CIT0005]--[@CIT0007] Many studies have been carried out using dopamine transporter imaging worldwide and the results are inconsistent.[@CIT0008]--[@CIT0011] 18F-AV133 is a tracer targeting for the vesicular monoamine transporter (VMAT2), which has little metabolism in the body and has better stability.[@CIT0012],[@CIT0013] There are few reports of basal ganglia lesions in this way. The aim of this study was to explore the mechanisms of FOG and provide exact evidence for the management of FOG.Figure 1Flow chart of all subjects through the study.**Abbreviations:** PD, Parkinson's disease; PET-CT, positron emission tomography--computed tomography; MRI, magnetic resonance imaging; MSA, multisystem atrophy; PSP, progressive nuclear paralysis; INPH, idiopathic normal pressure hydrocephalus; FOG, freezing of gait.

Methods {#S0002}
=======

Standard protocol approvals and patient consents {#S0002-S2001}
------------------------------------------------

The present study was approved by the Ethics Committee of Xuanwu Hospital, Capital Medical University, Beijing, People\'s Republic of China. The methods were carried out in accordance with the approved guidelines. Written informed consent was obtained from all subjects. This study complied with the guidelines of Capital Medical University, which abided by the Helsinki Declaration on ethical principles for medical research.

Study population {#S0002-S2002}
----------------

All cases were recruited consecutively from inpatients of the neurological department at Xuanwu Hospital, Capital Medical University of China. PD was established as a probable disease by the movement disorder specialists according to the criteria of the UK Brain Bank. Patients with secondary parkinsonism or other forms of atypical parkinsonism were excluded. The first cardinal feature and the age of appearance were reviewed rigorously and supervised by neurologists and specialists (see figure 1).

The definition of FOG {#S0002-S2003}
---------------------

The status of FOG was assessed on admission by their doctors in charge and experienced neurologists from clinical observation and inquiry with the patient himself/herself or caregivers. We also determined FOG by patients' responses to the question: "Do you feel that your feet get glued to the floor while walking, making a turn, or when trying to initiate walking?" Patients who answered "yes" were identified as freezers.

Clinical assessments {#S0002-S2004}
--------------------

We selected the time of discharge to assess the score for the Hoehn--Yahr stage[@CIT0014] and the unified Parkinson's disease rating scale (UPDRS),[@CIT0015] which were used to evaluate the disease severity of PD patients.[@CIT0015] The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were administered to all of the enrolled subjects in order to assess the presence of cognitive impairment.[@CIT0016],[@CIT0017] To evaluate the role of pharmacotherapy, the levodopa equivalent dose was calculated for all of the PD patients.[@CIT0018]

^18^F-AV133 PET and CT image processing {#S0002-S2005}
---------------------------------------

The \[^18^F\]-DTBZ radiotracer (^18^F-AV133) was prepared from aqueous \[^18^F\]-fluoride. Brain scans were acquired over an approximately 20-min period, 120 min after injection of approximately 250 MBq of ^18^F-AV133. Images were reconstructed using iterative reconstruction. Florbenazine images were spatially normalized to a standard atlas using an ^18^F-AV133 PET template. Atlas-based volumes of interest were applied for target areas (caudate, anterior and posterior putamen, and total striatum). The ratio of tracer activity in the target volumes of interest relative to the occipital cortex as a reference region was calculated to create the standard uptake value ratio.[@CIT0031]--[@CIT0033]

Three experienced radiologists read the image together, observed it visually, and synthesized the three axial images to judge the distribution of radioactivity in each part. The metabolic status of perivascular cortex or subcortical nucleus was assessed by 18-fludeoxyglucose positron emission tomography--computed tomography (^18^F-FDG PET-CT) and compared with the contralateral cerebral hemisphere. NeuroQ software (Philip Company) was used to process the ^18^F-FDG PET-CT brain imaging. After rigid deformation, the whole brain was divided into 24 regions. By comparison with the reference area, the metabolism of each region was calculated. The cerebellum was defined as the reference region because the Lewy body of cerebellar pathology has not been demonstrated unequivocally in different stages of PD. The most decreased ^18^F-FDG uptake regions of PET images were identified by NeuroQ software. The brain areas were automatically outlined by Scenium software and the mean standard uptake value was calculated between the two groups.

Statistical analysis {#S0002-S2006}
--------------------

Analyses were performed with Statistical Package for the Social Sciences (SPSS) statistics (version 20.0; IBM Corporation, Armonk, NY, USA). The sex difference was explored between the FOG group and the non-FOG group by chi-square analysis and logistic regression. The data of age, age of onset, duration, MMSE, MoCA, equivalent and current levodopa dose, VMAT2, and brain region uptake ratio were analyzed by variance and covariance between the FOG group and the non-FOG group. The correlation of FOG with clinical features, dopamine level, and uptake ratio of brain regions was conducted by bicorrelation and partial correlation. The significant difference was *p*\<0.05.

Results {#S0003}
=======

Risk factors and predictors of freezing gait {#S0003-S2001}
--------------------------------------------

A total of 167 cases with PD were recruited into the study which included 20 cases (11.98%) with FOG and 147 cases (88.02%) without FOG. The mean age was 66.86±2.57 years in PD patients with FOG while it was 56.46±0.94 years in those without FOG. PD patients with FOG were older than those without FOG after adjusting for sex by covariate analysis (*p*\<0.05). The age of onset was not significantly different between the FOG group and the non-FOG group after adjusting for sex by covariate analysis (56.17±3.12 years vs 52.48±1.15 years, *p*\>0.05). The duration of PD was significantly longer in the FOG group than that in the non-FOG group (11.93±1.23 years vs 3.69±0.44 years, *p*\<0.05). The ratios of FOG were 4.17%, 11.54%, and 47.06%, respectively, at no more than 2 years, 2--10 years, and more than 10 years of the disease. A sex difference was not observed whether PD patients had FOG or not (11.22 years vs 13.02%, *p*\>0.05) after adjusting for age by logistic regression (11.22 years vs 13.02%, *p*\>0.05).

The scores of Hoehn--Yahr stage and UPDRS-Ⅲ were not significantly higher in patients with FOG than in those without FOG by variance and covariance analysis (2.20±0.15 and 41.04±4.29 vs 2.00±0.06 and 37.54±1.36, *p*\>0.05). The dose of levodopa was higher in the FOG group compared with that in the non-FOG group after adjusting for age and sex by covariance (738.56±80.37 mg vs 530.90±28.68 mg, *p*\<0.05).

The mean scores of MMSE and MoCA were 20.29±1.15 and 20.41±2.69, respectively, in patients with FOG, and higher than those in PD patients without FOG (*p*\<0.05). After adjusting for age and sex by covariance analysis, there were still significant differences of MMSE and MoCA between the two groups (23.49±1.04 and 21.63±1.03 vs 26.96±0.35 and 24.43±0.35, *p*\<0.05) (see [Table 1](#T0001){ref-type="table"}). Table 1Analysis of clinical characteristics in PD patients with FOGCharacteristicBefore adjustmentAfter adjustmentFOG groupNon-FOG group*p*FOG groupNon-FOG group*p*Age (years), mean±SD66.90±1.5156.33±0.980.0066.86±2.5756.46±0.940.00Age of onset (years), mean±SD56.25±3.2052.47±1.150.2656.17±3.1252.48±1.150.27Duration10.65±2.253.86±0.380.0011.93±1.233.69±0.440.00 ≤2 years, n (%)3 (4.17)69 (95.83) 2--10 years, n (%)9 (11.54)69 (88.46) ≥10 years, n (%)8 (47.06)9 (52.94)Sex Male, n (%)11 (11.22)87 (88.78)0.7211 (11.22)87 (88.78)0.88 Female, n (%))9 (13.04)60 (86.96)9 (13.04)60 (86.96)Hoehn--Yahr stage2.25±0.121.99±0.060.102.20±0.152.00±0.060.21UPDRS59.25±1.9668.30±4.950.5347.53±12.3669.72±4.210.09UPDRS-III43.36±4.0237.30±1.390.1841.04±4.2937.54±1.360.44MMSE22.41±1.4927.09±0.340.0023.49±1.0426.96±0.350.00MoCA20.29±1.1524.60±0.370.0021.63±1.0324.43±0.350.01Equivalent levodopa dose (mg)704.08±51.34535.59±29.610.04738.56±80.37530.90±28.680.02[^1][^2]

The difference of dopamine level shown by VMAT2 with ^18^F-AV133 between the two groups {#S0003-S2002}
---------------------------------------------------------------------------------------

The mean uptake ratio of VMAT2 with ^18^F-AV133 in the putamen was significantly lower in the FOG group than in the non-FOG group (6.51±0.29 vs 7.46±0.26, *p*\<0.05). After adjusting for age and sex, the uptake ratio of VMAT2 was still lower in patients in the FOG group than in the non-FOG group (6.26±0.51 vs 7.52±0.18, *p*\<0.05). We further stratified the putamen into the anterior and dorsal putamen and found that the uptake ratio of VMAT2 decreased more obviously in the dorsal putamen in patients with FOG than in those without FOG after adjusting for age and sex by covariance (2.77±0.25 vs 3.32±0.09, *p*\<0.05). Single-factor analysis found that the uptake ratio of VMAT2 in the caudate nucleus was significantly lower in the FOG group compared with that in the non-FOG group (4.43±0.25 vs 5.36±0.14, *p*\<0.05). But there was no significant difference of VMAT2 distribution in the caudate nucleus between the two groups after adjusting for age and sex by covariance analysis (*p*\>0.05) (see [Table 2](#T0002){ref-type="table"} and [Figures 2](#F0002){ref-type="fig"}, [3](#F0003){ref-type="fig"}, [4](#F0004){ref-type="fig"}, [5](#F0005){ref-type="fig"}). Table 2Uptake ratio of VMAT2 distribution by ^18^F-FDG PET-CT in PD patients with FOGBrain regionBefore adjustmentAfter adjustmentFOG groupNon-FOG group*p*FOG groupNon-FOG group*p*Caudate nucleus4.43±0.255.36±0.140.024.74±0.365.32±0.140.15Putamen6.51±0.297.46±0.260.076.26±0.517.52±0.180.02Anterior putamen3.59±0.174.18±0.110.053.50±0.294.20±0.100.02Dorsal putamen2.92±0.153.30±0.100.152.77±0.253.32±0.090.04[^3][^4] Figure 2Activities of VMAT2 between the two groups.**Abbreviation:** FOG, freezing of gait.Figure 3PET-CT image of VMAT2 distribution in a Hoehn--Yahr stage 3 patient with freezing of gait. Two white arrows indicate severe dopamine decline of bilateral putamens in cases.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.Figure 4PET-CT image of VMAT2 distribution in a Hoehn--Yahr stage 3 patient without freezing of gait. Two white arrows show the dopamine decline of bilateral putamen.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.Figure 5PET-CT image of VMAT2 distribution in a normal person. Two white arrows show the normal dopamine level of bilateral putamen.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.

[Figure 2](#F0002){ref-type="fig"} shows that the dopamine level of the nigrostriatal system decreased significantly in the FOG group compared with the non-FOG group.

[Figure 3](#F0003){ref-type="fig"} shows that the dopamine level of the nigrostriatal system declined obviously in a patient with FOG at Hoehn--Yahr stage 3 compared with a normal person and a patient with non-FOG.

[Figure 4](#F0004){ref-type="fig"} shows that the dopamine level of the nigrostriatal system declined obviously in a patient without FOG at Hoehn--Yahr stage 3 compared with a normal person and was higher than that in a patient with FOG.

[Figure 5](#F0005){ref-type="fig"} shows that the dopamine level of the nigrostriatal system was normal.

The association between FOG and activities of brain regions by ^18^F-FDG PET-CT in PD {#S0003-S2003}
-------------------------------------------------------------------------------------

The whole brain was divided into 24 regions by NeuroQ software. Our data found that the mean uptake ratios of the caudate nucleus and lentiform nucleus were higher in patients with FOG than those without FOG by variance analysis (*p*\<0.05). After adjusting for age and sex by covariance, the mean uptake ratios of the caudate nucleus and lentiform nucleus were still higher in the FOG group compared with those without FOG (*p*\<0.05). The mean uptake ratio of the left primary visual cortex was significantly lower in the FOG group than that in the non-FOG group after adjusting for age and sex by covariance analysis (*p*\<0.05). There were no differences of uptake ratios detected by ^18^F-FDG PET-CT in other brain areas between the FOG group and the non-FOG group by variance and covariance analysis (*p*\>0.05) (see [Table 3](#T0003){ref-type="table"} and [Figures 6](#F0006){ref-type="fig"}, [7](#F0007){ref-type="fig"}, [8](#F0008){ref-type="fig"}, [9](#F0009){ref-type="fig"}). Table 3Uptake ratios of different brain regions by ^18^F-FDG PET-CT in PD patients with FOGBrain regionBefore adjustmentAfter adjustmentFOG groupNon-FOG group*p*FOG groupNon-FOG group*p*Midbrain0.85±0.030.84±0.010.490.87±0.020.84±0.010.14Caudate nucleus1.10±0.031.07±0.010.161.12±0.02\*1.06±0.010.03Lentiform nucleus1.41±0.04\*1.32±0.010.011.40±0.03\*1.33±0.010.045Thalamus1.21±0.041.18±0.010.211.21±0.031.18±0.010.18Medial frontal cortex1.15±0.031.13±0.010.641.14±0.031.13±0.010.85Superior frontal cortex1.14±0.041.10±0.010.211.14±0.031.10±0.010.27Middle frontal cortex1.24±0.041.21±0.010.301.24±0.031.21±0.010.36Inferior frontal cortex1.22±0.03\*1.17±0.010.061.22±0.031.17±0.010.06Sensorimotor cortex1.16±0.031.12±0.010.081.16±0.031.12±0.010.16Broca region1.24±0.041.20±0.010.251.24±0.031.20±0.010.29Anterior cingulate cortex1.15±0.031.17±0.010.691.16±0.031.17±0.010.74Posterior cingulate cortex1.36±0.041.34±0.010.671.35±0.041.34±0.010.86Superior parietal cortex1.06±0.031.01±0.010.061.04±0.021.02±0.010.23Inferior parietal cortex1.10±0.031.05±0.010.101.09±0.031.06±0.010.19Parietal temporal cortex1.15±0.041.12±0.010.311.16±0.031.12±0.010.20Superior lateral temporal cortex1.21±0.031.17±0.010.191.21±0.031.17±0.010.17Inferior lateral anterior temporal cortex1.00±0.030.97±0.010.271.01±0.020.97±0.010.12Inferior lateral posterior temporal cortex1.07±0.031.05±0.010.351.08±0.021.05±0.010.21Anterior medial temporal cortex0.82±0.020.81±0.070.550.83±0.020.81±0.010.21Posterior medial temporal cortex1.02±0.030.98±0.010.341.02±0.021.00±0.010.19Primary visual cortex1.18±0.06\*1.27±0.010.041.19±0.04\*1.27±0.020.049Associated visual cortex1.17±0.041.15±0.010.631.17±0.031.15±0.010.59[^5][^6] Figure 6Activities of different brain regions between the two groups.**Abbreviation:** FOG, freezing of gait.Figure 7PET-CT image of Hoehn--Yahr stage 3 patient with freezing of gait. Two white arrows show hypometabolism of bilateral primary visualcortex.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.Figure 8PET-CT imageof Hoehn--Yahr stage 3 patient without freezing of gait. Two white arrows indicate hypermetabolism of bilateral primary visualcortex.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.Figure 9PET-CT image of a normal person. Two white arrows show the normal metabolism of primary visualcortex.**Abbreviation:** PET-CT, positron emission tomography--computed tomography.

[Figure 6](#F0006){ref-type="fig"} shows that activities of the nigrostriatal system increased significantly in the FOG group compared with the non-FOG group while the activity of the primary visual cortex decreased obviously in the FOG group.

[Figure 7](#F0007){ref-type="fig"} shows that the activity of the primary visual cortex decreased obviously in a patient with FOG compared with a normal person ([Figure 9](#F0009){ref-type="fig"}) and a non-FOG PD patient ([Figure 8](#F0008){ref-type="fig"}).

Discussion {#S0004}
==========

FOG is a common disabling symptom mainly at the advanced stage of disease and the prevalence has varied from 7% in PD patients with a recent diagnosis to 63%.[@CIT0019],[@CIT0020],[@CIT0021] FOG prevalence reflects a mixed population of patients with early and advanced disease, most of whom could be improved by dopaminergic drugs. The ratio of FOG was 11.98% in our study and mainly occurred in the elderly. This frequency was lower than that of previous studies in China, and may be due to the hospital studied and patients selected. Male predominance was not observed in PD patients with FOG, in which the ratio was 11.22%.

Our data found that the ratio of FOG increased as the disease progressed and was strongly related to the duration. The ratio of FOG ranged from 4.17% at 2 years of the disease to 47.06% after 10 years. The dose of equivalent levodopa was also significantly higher in patients with FOG at discharge than in persons without FOG. This result suggested that patients with FOG needed more dopaminergic drugs in order to improve motor symptoms and reach a nearly normal life compared with those without FOG. This phenomenon was also observed in other studies in which patients with FOG needed more dopaminergic drugs and were mainly in the advanced stage of PD.[@CIT0021],[@CIT0022] Our data did not find that FOG was associated with the motor severity according to the scores of Hoehn--Yahr stage and UPDRS-Ⅲ. The reason for this was that patients with PD could be restored to nearly normal life by reasonable plans with anti-Parkinson drugs, rehabilitation, and psychological support. Therefore, the Hoehn--Yahr and UPDRS-Ⅲ scores could be reduced by appropriate therapy. This result was contrary to previous studies in which FOG was strongly related to the severity of PD according to Hoehn--Yahr and UPDRS-Ⅲ scores, and the bias may come from the assessment time and sample selection.

The pathophysiology of FOG is not well understood but is thought to also be driven by impairments of multiple brain areas. Previous studies reported that FOG was related to cognitive dysfunction, for which cognitive training is an effective intervention and may lessen the severity of FOG.[@CIT0005],[@CIT0006],[@CIT0016] Then, it is plausible that cognitive impairment may partly underlie the mechanisms of FOG. Our data also found that the scores of the MMSE and MoCA were significantly decreased in patients with FOG. This indicated that cognitive function was involved in the onset of FOG.

PET studies have allowed us to gain important insights into the functions of the dopaminergic system and non-dopaminergic system in PD. VMAT2 is the protein responsible for transporting dopamine and is likely to allow us to directly assess degeneration of the substantia nigra neuron and dopamine level in the living PD brain. Up to date, few studies on the VMAT2 distribution or ^18^F-FDG metabolism by PET-CT imaging have been performed in PD.[@CIT0023] Our data showed that the VMAT2 distribution with ^18^F-AV133 was decreased in PD patients with FOG compared with those without FOG. This indicated that the degeneration of the nigrostriatal system was more severe and the dopamine level was significantly lower in PD patients with FOG compared with those without FOG. The reason for this was that the dopamine level was markedly depleted and motor symptoms were remarkably aggravated as the substantia nigra was largely impaired by Lewy bodies. This was consistent with our clinical observations in which patients with FOG had a longer duration and more doses of dopaminergic drugs.

The reason for selecting the cerebellum as the reference region was that the Lewy body of cerebellar pathology has not been demonstrated unequivocally in different stages of PD.[@CIT0024],[@CIT0025] The mean uptake ratios of different brain regions were defined by comparison with the reference region. We found that the uptake ratios of the caudate nucleus and lentiform nucleus were higher in patients with FOG than in those without FOG by ^18^F-FDG PET-CT imaging. Increased metabolism of the caudate nucleus and lentiform nucleus may relate to the plastic changes of these areas in order to compensate for the decreased dopamine level of the nigrostriatal system.[@CIT0026],[@CIT0027] Our data also showed that the uptake ratio of the primary visual cortex was significantly lower in patients with FOG compared with those without FOG, and indicated that the impairment of the primary visual cortex partly accounted for the occurrence of FOG. This was consistent with previous reports that FOG came from the result of cognitive or sensorimotor dysfunction, and rehabilitation with visual cues could partly alleviate FOG.[@CIT0028],[@CIT0029]

Assessment of FOG in the context of PD remains ill-defined and poorly understood, making generalizations difficult. Various methods of FOG assessment are implemented across different studies.[@CIT0030] Another limitation of our study came from the sample selection, with all participants being inpatients of our PD unit.

In summary, this was the first study to investigate the activities of different brain regions by PET-CT and found that the dopaminergic pathway and primary visual cortex may be involved in the pathogenesis of FOG. FOG was more common in the advanced stage of PD. The ratio of FOG was strongly associated with the duration. A large dose of dopaminergic drugs was needed to alleviate the motor symptoms of PD with FOG. The dopamine level, which was shown by VMAT2 with ^18^F-AV133 PET-CT, was decreased significantly in patients with FOG. This result also implied that FOG was not just a motor symptom but an important predictor for the advanced stage of PD. Metabolism of the primary visual cortex by ^18^F-FDG PET-CT decreased significantly in patients with FOG compared with those without FOG. This provided evidence that the management of FOG needs to not only provide an appropriate dose of dopaminergic drugs, but also take an active part in cognitive training with visual cues.
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[^1]: **Notes:** Single-factor analysis by variance and chi-square analysis. Adjusting confounding factors by covariate and logistic analysis. \**p*\<0.05.

[^2]: **Abbreviations:** PD, Parkinson's disease; FOG, freezing of gait; UPDRS, unified Parkinson\'s disease rating scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment.

[^3]: **Notes:** Single-factor analysis by variance and adjusting confounding factors by covariate analysis. \**p*\<0.05.

[^4]: **Abbreviations:** ^18^F-FDG PET-CT, 18-fludeoxyglucose positron emission tomography--computed tomography; PD, Parkinson's disease; FOG, freezing of gait.

[^5]: **Notes:** Single-factor analysis by variance and adjusting confounding factors by covariate analysis. \**p*\<0.05.

[^6]: **Abbreviations:**^18^F-FDG PET-CT, 18-fludeoxyglucose positron emission tomography--computed tomography; PD, Parkinson's disease; FOG, freezing of gait.
